UAR Journal of Multidisciplinary Studies (UARJMS)
ISSN: XXXX-XXXX (Online)
Journal Home Page
Volume- I Issue- I (March) 2025
Frequency: Monthly

Review Article

Clinical Outcomes of Antiretroviral Therapy in Sickle Cell Disease: A Review

*Emmanuel Ifeanyi Obeagu[1] and Francisca Ifeoma Osunwanne[2]

[1]Department of Biomedical and Laboratory Science, Africa University, Zimbabwe,
[2]Department of Nursing Science, Faculty of Health Sciences, Imo State University, Owerri, Imo State, Nigeria.

***Corresponding author:** Emmanuel Ifeanyi Obeagu

Abstract

The coexistence of HIV and sickle cell disease (SCD) presents unique clinical challenges due to overlapping pathophysiological mechanisms, including chronic inflammation, immune dysregulation, and endothelial dysfunction. While antiretroviral therapy (ART) has significantly improved survival and quality of life in HIV-infected individuals, its impact on SCD progression remains an area of concern. Some ART regimens may exacerbate anemia, increase oxidative stress, and impair vascular function, potentially influencing the frequency and severity of vaso-occlusive crises (VOCs). Conversely, effective viral suppression through ART may reduce systemic inflammation and immune activation, potentially benefiting SCD-related complications. This review explores the clinical outcomes of ART in SCD patients, focusing on its effects on VOC frequency, anemia, endothelial function, and long-term disease progression. The choice of ART regimen plays a crucial role in mitigating hematologic and vascular complications, with certain drugs, such as zidovudine, being associated with bone marrow suppression and anemia, while integrase inhibitors demonstrate a more favorable safety profile. Additionally, ART may influence endothelial health, with protease inhibitors linked to endothelial dysfunction, while newer regimens may have neutral or even protective effects. Given these complexities, individualized ART selection is essential for optimizing treatment outcomes in HIV-SCD co-infected patients.

Keywords: Antiretroviral therapy, sickle cell disease, vaso-occlusive crisis, anemia, endothelial dysfunction

Introduction

Sickle cell disease (SCD) is a genetic hematological disorder characterized by the production of abnormal hemoglobin, leading to the deformation of red blood cells (RBCs) into a sickle shape. This deformation results in various complications, including vaso-occlusive crises (VOCs), hemolytic anemia, and increased susceptibility to infections. The World Health Organization (WHO) estimates that approximately 300,000 infants are born with SCD each year, predominantly in sub-Saharan Africa, India, and the Middle East. The chronic complications of SCD significantly impact the quality of life and lead to premature mortality. Effective management strategies are essential to mitigate these complications and improve patient outcomes.[1-3] HIV infection, a major global health challenge, affects millions of individuals worldwide, particularly in regions where SCD is endemic. The interaction between HIV and SCD is complex, as both conditions share common pathophysiological mechanisms, including chronic inflammation, immune dysregulation, and endothelial dysfunction. HIV-induced immune suppression can exacerbate the complications of SCD, leading to increased VOC frequency, worsening anemia, and a higher risk of infections. This co-infection poses unique clinical challenges, necessitating a thorough understanding of the interplay between these two diseases.

Antiretroviral therapy (ART) has transformed HIV management, significantly reducing morbidity and mortality associated with the virus. Effective ART can restore immune function, reduce HIV-related inflammation, and improve overall health. However, the impact of ART on SCD remains an area of active investigation, as certain ART regimens may have adverse effects on hematologic parameters and vascular function. For instance, some drugs can lead to bone marrow suppression and anemia, potentially worsening SCD complications. Conversely, effective viral suppression through ART may alleviate inflammation and reduce the frequency of VOCs, highlighting the need for a careful evaluation of ART regimens in HIV-SCD co-infected patients.[4-7]

The choice of ART regimen is critical in managing co-infected individuals, as some drugs may exacerbate SCD-related complications. For example, zidovudine (AZT) is known to cause hematologic toxicity, leading to worsened anemia in SCD patients. In contrast, newer ART agents, such as integrase inhibitors, are associated with fewer hematologic adverse effects and may provide a more favorable safety profile. Understanding these differences is essential for optimizing treatment strategies and improving patient outcomes in this vulnerable population.[8-9] Recent studies have begun to explore the clinical outcomes of ART in SCD patients,

focusing on its effects on VOC frequency, anemia, endothelial function, and long-term disease progression. Preliminary evidence suggests that effective ART may reduce systemic inflammation and improve endothelial health, which could benefit SCD patients. However, the existing literature is limited, and further research is needed to elucidate the complex interactions between HIV, ART, and SCD pathophysiology.[10-11] This review aims to provide an overview of the clinical outcomes of ART in SCD patients, highlighting the effects on VOC frequency, anemia, and endothelial dysfunction.

Effects of Antiretroviral Therapy on Vaso-Occlusive Crises

Vaso-occlusive crises (VOCs) are a hallmark of sickle cell disease (SCD) and represent one of the most significant complications faced by patients. VOCs occur when sickled red blood cells (RBCs) obstruct blood flow in the microvasculature, leading to pain, ischemia, and tissue damage. In HIV-infected individuals with SCD, the frequency and severity of VOCs may be influenced by various factors, including immune status, inflammatory mediators, and the specific antiretroviral therapy (ART) regimen employed.[12-13] The use of ART in managing HIV infection has profound implications for the immune system and systemic inflammation, both of which play critical roles in the pathogenesis of VOCs. Effective ART can lead to significant reductions in viral load, improved immune function, and a decrease in inflammatory cytokines. Studies suggest that well-controlled HIV infection can mitigate some of the inflammatory processes that exacerbate SCD-related complications, potentially leading to a reduction in VOC frequency. By restoring immune balance, ART may contribute to better vascular health and decreased incidence of VOCs in co-infected individuals.[14-15] However, the effects of specific ART regimens on VOC frequency can vary. Some ART drugs, particularly certain protease inhibitors (PIs), have been associated with adverse effects that may exacerbate endothelial dysfunction and oxidative stress, which are known contributors to VOCs. For example, PIs can induce inflammation and may lead to metabolic complications, such as lipid abnormalities and insulin resistance, which could further impair endothelial function and increase the risk of vascular occlusion. In contrast, newer classes of ART, such as integrase inhibitors, appear to have a more favorable safety profile regarding hematologic and vascular effects, potentially offering better outcomes for patients with SCD.[16-17] Furthermore, the interaction between ART and sickle cell pathophysiology is complex. While effective ART may alleviate some of the inflammatory processes associated with HIV, it is essential to consider the potential hematologic toxicity of certain medications. Drugs like zidovudine (AZT) can cause bone marrow suppression, leading to worsened anemia, which is already a significant concern in SCD. Anemia can further exacerbate the frequency and severity of VOCs by decreasing the oxygen-carrying capacity of the blood and contributing to hypoxia in tissues, thereby triggering more frequent crises.[18-19]

Impact of Antiretroviral Therapy on Anemia and Hematologic Parameters

Anemia is a prevalent complication in sickle cell disease (SCD) and is often exacerbated by co-existing conditions, such as HIV. The interplay between these two conditions can significantly affect hematologic parameters, including hemoglobin levels, red blood cell (RBC) counts, and overall blood health. Antiretroviral therapy (ART) has been shown to influence anemia in individuals with HIV and SCD, with various ART regimens producing different effects on hematologic parameters.[20-21] One of the primary challenges in managing anemia in HIV-SCD co-infected patients is the hematologic toxicity associated with certain ART medications. For instance, drugs such as zidovudine (AZT) are well-documented for their potential to cause bone marrow suppression, leading to a decrease in RBC production and exacerbating anemia in SCD patients. Given that individuals with SCD already experience chronic hemolytic anemia, the additional insult from AZT can result in critically low hemoglobin levels, increasing the risk of complications and affecting overall health. Consequently, careful consideration of the ART regimen is essential to minimize hematologic toxicity while maintaining effective HIV control.[22-23] In contrast, newer classes of ART, particularly integrase inhibitors, have shown a more favorable impact on hematologic parameters. These drugs are associated with fewer instances of bone marrow suppression and are less likely to contribute to anemia. By avoiding the hematologic complications associated with older ART regimens, integrase inhibitors may help improve hemoglobin levels and reduce the overall burden of anemia in co-infected patients. Furthermore, by effectively suppressing HIV replication, these agents can enhance immune function and decrease chronic inflammation, both of which can indirectly benefit hematologic health.[24-25]

Moreover, effective ART can lead to improvements in overall health, which may positively impact hematologic parameters. By controlling viral load and enhancing immune function, ART can reduce the incidence of infections and inflammatory processes that contribute to anemia. For example, chronic inflammation and opportunistic infections in HIV-infected individuals can lead to anemia of inflammation, characterized by impaired erythropoiesis and increased RBC destruction. By managing HIV effectively, ART may reduce the severity of these inflammatory responses, ultimately benefiting the hematologic profile of patients with SCD.[26-27] The impact of ART on anemia and hematologic parameters in SCD patients highlights the need for individualized treatment approaches. Clinicians must carefully assess the potential risks and benefits of specific ART regimens, particularly in relation to their effects on blood health. Close monitoring of hemoglobin levels and other hematologic parameters is essential in managing co-infected individuals, allowing for timely interventions to address anemia and optimize overall health outcomes.[28-29]

Antiretroviral Therapy and Endothelial Dysfunction in Sickle Cell Disease

Endothelial dysfunction is a critical factor contributing to the vascular complications observed in sickle cell disease (SCD). In SCD, the abnormal sickle-shaped red blood cells can cause mechanical obstruction in the microcirculation, leading to ischemia and reperfusion injury, which exacerbates endothelial injury. Additionally, chronic hemolysis releases free hemoglobin into the circulation, which scavenges nitric oxide (NO), a vital molecule for endothelial health and vasodilation. This results in reduced bioavailability of NO, promoting vasoconstriction and inflammation, further worsening endothelial dysfunction. The interplay between SCD and HIV complicates this scenario, as both conditions can contribute to increased endothelial dysfunction through overlapping mechanisms, such as chronic inflammation and immune dysregulation.[30-31] Antiretroviral therapy (ART) has significantly advanced the management of HIV, reducing viral load

and improving immune function. However, the effects of ART on endothelial dysfunction in individuals with HIV-SCD co-infection are complex and can vary depending on the specific ART regimen used. Certain classes of ART, particularly protease inhibitors (PIs), have been associated with metabolic side effects that can adversely affect endothelial function. For example, PIs can lead to lipid abnormalities and insulin resistance, which are known risk factors for endothelial dysfunction. The accumulation of visceral fat and the resulting pro-inflammatory state can further exacerbate endothelial injury, increasing the risk of vascular complications in co-infected patients.[32-33]

In contrast, newer ART regimens, such as integrase inhibitors, tend to have a more favorable metabolic profile. These agents are less likely to cause lipid dysregulation and insulin resistance, potentially mitigating some of the adverse effects on endothelial function. Effective viral suppression through these newer agents may also lead to a reduction in systemic inflammation, which could benefit endothelial health. Improved immune function and reduced inflammatory cytokines may enhance the endothelial response and restore vascular homeostasis, ultimately decreasing the incidence of vaso-occlusive crises (VOCs) and other vascular complications.[34-35] Furthermore, effective ART may influence endothelial function through its impact on oxidative stress. Chronic HIV infection is associated with increased oxidative stress, which can impair endothelial function and contribute to vascular complications. By effectively controlling viral replication and reducing immune activation, ART may help alleviate oxidative stress, promoting better endothelial function in co-infected individuals. This aspect is particularly crucial for SCD patients, who are already at an elevated risk for endothelial dysfunction due to their underlying disease processes.[36-37] Additionally, the use of ART in HIV-SCD co-infected patients necessitates a comprehensive approach that considers the unique needs of this population. Clinicians should monitor for potential complications associated with both HIV and SCD, including endothelial dysfunction, and tailor ART regimens accordingly. This may involve selecting ART options that minimize adverse metabolic effects while ensuring effective viral suppression and immune recovery. Regular assessment of endothelial function through clinical markers and patient-reported outcomes can also aid in optimizing management strategies for co-infected individuals.[38]

Long-Term Outcomes and Disease Progression in Sickle Cell Disease with Antiretroviral Therapy

The long-term outcomes of individuals with sickle cell disease (SCD) who are co-infected with HIV and receiving antiretroviral therapy (ART) are crucial for understanding disease management and improving quality of life. The intersection of these two chronic conditions presents unique challenges, as both SCD and HIV can lead to significant morbidity and mortality.[39] One of the primary concerns in managing patients with SCD and HIV is the potential for accelerated disease progression. SCD is associated with various complications, including vaso-occlusive crises (VOCs), chronic pain, acute chest syndrome, and organ damage. The presence of HIV can further exacerbate these issues through immune dysregulation and increased susceptibility to infections. However, effective ART can significantly alter this trajectory by controlling HIV replication, improving immune function, and reducing the incidence of opportunistic infections. Patients who maintain viral suppression with ART often experience improved overall health, which can mitigate the adverse effects of both HIV and SCD on long-term outcomes.[40] Recent studies have indicated that individuals with HIV and SCD who receive effective ART may have comparable life expectancy and health status to those with SCD alone. This improvement can be attributed to the enhanced management of HIV, which reduces the systemic inflammation and immune compromise associated with uncontrolled viral replication. Additionally, ART may indirectly benefit SCD management by decreasing the frequency and severity of VOCs and other complications through improved immune function and reduced oxidative stress. However, careful selection of ART regimens is essential, as certain medications may introduce metabolic side effects that can negatively impact SCD management.[41]

Despite the advancements in ART and its positive impact on disease progression, there are still significant long-term challenges faced by co-infected patients. Chronic hemolysis, which is inherent to SCD, can lead to persistent anemia and other hematologic complications that may be exacerbated by ART-related toxicity. Medications such as zidovudine (AZT) have been associated with bone marrow suppression, which can further complicate the anemia already experienced by individuals with SCD. Therefore, ongoing monitoring of hematologic parameters and adjustments to the ART regimen may be necessary to optimize long-term outcomes in this population.[42] Moreover, the psychological and social aspects of living with both SCD and HIV can also influence long-term outcomes. The stigma associated with both conditions can affect mental health, treatment adherence, and overall well-being. Integrated care approaches that address the psychosocial needs of patients, in addition to their medical management, are critical for improving quality of life and long-term health outcomes. Collaborative care models that involve hematologists, infectious disease specialists, and mental health professionals can help create a comprehensive management plan that addresses the multifaceted needs of co-infected individuals.[43]

Therapeutic Considerations for Managing Sickle Cell Disease in Patients with HIV

Managing individuals with sickle cell disease (SCD) who are co-infected with HIV presents unique therapeutic challenges and considerations. The interaction between these two chronic conditions necessitates a comprehensive and individualized approach to treatment, ensuring that both SCD and HIV are effectively managed while minimizing potential complications. Therapeutic considerations encompass medication selection, monitoring for adverse effects, and addressing the psychosocial needs of patients.

1. Antiretroviral Therapy (ART) Selection

The selection of an appropriate ART regimen is crucial for individuals with HIV and SCD. Certain antiretroviral agents, particularly those associated with hematologic toxicity, can exacerbate anemia and other complications related to SCD. For example, zidovudine (AZT) is known to cause bone marrow suppression, which can significantly worsen the hemolytic anemia already present in SCD. Therefore, healthcare providers should consider utilizing ART regimens that are less likely to impact hematologic parameters negatively. Integrase inhibitors, such as dolutegravir and bictegravir, have shown a more favorable safety profile in this regard and may be preferable options for co-infected patients.[44]

2. Monitoring and Management of Hematologic Parameters

Regular monitoring of hematologic parameters is essential in managing patients with SCD and HIV. This includes assessing hemoglobin levels, red blood cell counts, and reticulocyte counts to evaluate the degree of anemia and response to treatment. Given the potential for ART-related toxicity, particularly with older nucleoside reverse transcriptase inhibitors (NRTIs), it is essential to adjust the ART regimen as needed to optimize hematologic health. Additionally, clinicians should be vigilant for signs of opportunistic infections and inflammatory responses, as these can further complicate anemia and overall health.[45]

3. Pain Management and Supportive Care

Effective pain management is a cornerstone of SCD treatment, especially during vaso-occlusive crises (VOCs). Pain can be exacerbated by infections, including those related to HIV. A multimodal approach to pain management that includes non-opioid analgesics, opioid medications, and adjunctive therapies such as physical therapy or acupuncture should be considered. Furthermore, supportive care measures, including hydration and oxygen therapy, can help mitigate the severity of VOCs and improve patient outcomes. Comprehensive care that addresses both the acute and chronic pain associated with SCD is essential for enhancing quality of life.[46]

4. Preventive Care and Vaccinations

Preventive care is particularly important for individuals with SCD and HIV, as they are at increased risk of infections. Vaccination against preventable diseases, such as influenza and pneumococcus, should be a routine part of their healthcare plan. Prophylactic antibiotics, such as penicillin, may also be necessary for young children with SCD to prevent life-threatening infections. Moreover, healthcare providers should educate patients about recognizing the signs of infection and seeking prompt medical attention to prevent complications.[47]

5. Psychosocial Support and Adherence

The management of chronic diseases like SCD and HIV often involves significant psychological and social stressors. Addressing the psychosocial needs of co-infected patients is vital for treatment adherence and overall well-being. Mental health support, counseling, and patient education can empower individuals to manage their conditions effectively. Moreover, engaging in community support groups can provide emotional support and foster a sense of belonging, reducing feelings of isolation often associated with living with multiple chronic conditions.[48]

Conclusion

The management of sickle cell disease (SCD) in patients co-infected with HIV presents a unique set of challenges that require a comprehensive and multidisciplinary approach. The interplay between these two chronic conditions significantly impacts patient outcomes, necessitating careful consideration of therapeutic strategies, particularly in the context of antiretroviral therapy (ART). Effective management hinges on selecting appropriate ART regimens that minimize hematologic toxicity while ensuring viral suppression, as well as vigilant monitoring of hematologic parameters and pain management.

The benefits of effective ART in improving immune function and reducing the incidence of opportunistic infections cannot be overstated. By addressing HIV effectively, healthcare providers can enhance the overall health and quality of life for patients with SCD. Furthermore, integrating psychosocial support and preventive care into the treatment plan is crucial, as these elements play a vital role in adherence to therapy and overall well-being.

References

1. Owusu ED, Visser BJ, Nagel IM, Mens PF, Grobusch MP. The interaction between sickle cell disease and HIV infection: a systematic review. Clinical Infectious Diseases. 2015; 60(4):612-626.
2. Boateng LA, Ngoma AM, Bates I, Schonewille H. Red blood cell alloimmunization in transfused patients with sickle cell disease in sub-Saharan Africa; a systematic review and meta-analysis. Transfusion Medicine Reviews. 2019; 33(3):162-169.
3. Ola B, Olushola O, Ebenso B, Berghs M. Sickle Cell Disease and Its Psychosocial Burdens in Africa. InSickle Cell Disease in Sub-Saharan Africa 2024: 67-80. Routledge.
4. Makani J, Ofori-Acquah SF, Nnodu O, Wonkam A, Ohene-Frempong K. Sickle cell disease: new opportunities and challenges in Africa. The scientific world journals. 2013; 2013(1):193252.
5. Ochocinski D, Dalal M, Black LV, Carr S, Lew J, Sullivan K, Kissoon N. Life-threatening infectious complications in sickle cell disease: a concise narrative review. Frontiers in Pediatrics. 2020; 8:38.
6. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology, 2024; 2(1): 14-33
7. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
8. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health, 2024; 2 (1): 52-61
9. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024; 10(1):25-36.
10. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Asian J Dental Health Sci, 2024; 4(1):32-7. Available from: http://ajdhs.com/index.php/journal/article/view/62
11. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health, 2024; 2 (1): 52-63
12. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science, 2024; 2(2):1-17
13. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV, 2024; 2(2): 60-73 1

14. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science, 2024; 2(2): 20- 35
15. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIVExposed Infants: A Review. Elite Journal of Immunology, 2024; 2(3): 1-18
16. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. Newport International Journal of Biological and Applied Sciences (NIJBAS) 2023. http://hdl.handle.net/20.500.12493/14626
17. Ntsekhe M, Baker JV. Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context. Circulation. 2023; 147(1):83-100.
18. Obare LM, Temu T, Mallal SA, Wanjalla CN. Inflammation in HIV and its impact on atherosclerotic cardiovascular disease. Circulation research. 2024; 134(11):1515-1545
19. Hmiel L, Zhang S, Obare LM, Santana MA, Wanjalla CN, Titanji BK, Hileman CO, Bagchi S. Inflammatory and immune mechanisms for atherosclerotic cardiovascular disease in HIV. International journal of molecular sciences. 2024; 25(13):7266..
20. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2(3): 10-24
21. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. Elite Journal of Immunology, 2024; 2(2): 15-28
22. Belisário AR, Blatyta PF, Vivanco D, Oliveira CD, Carneiro-Proietti AB, Sabino EC, de Almeida-Neto C, Loureiro P, Máximo C, de Oliveira Garcia Mateos S, Flor-Park MV. Association of HIV infection with clinical and laboratory characteristics of sickle cell disease. BMC Infectious Diseases. 2020; 20(1):638.
23. Bhowmik A, Banerjee P. Hematological manifestation in HIV infected children. J Coll Physicians Surg Pak. 2015; 25(2):119-123.
24. Gill AF, Ahsan MH, Lackner AA, Veazey RS. Hematologic abnormalities associated with simian immunodeficieny virus (SIV) infection mimic those in HIV infection. Journal of Medical Primatology. 2012; 41(3):214-224.
25. Nouraie M, Nekhai S, Gordeuk VR. Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in US hospital discharge records: a cross-sectional study. Sexually transmitted infections. 2012; 88(7):528-533.
26. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine. 2024; 2(1):33-45.
27. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health, 2024; 2 (1): 35-51
28. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 84-99
29. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology, 2024; 2(3): 33-44
30. Obeagu EI, Obeagu, GU. Impact of Blood Transfusion on Viral Load Dynamics in HIVPositive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 42-60
31. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies . Elite Journal of Laboratory Medicine, 2024; 2(2): 30-46
32. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV, 2024; 2(2): 43-59
33. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology, 2024; 2(3): 25-41
34. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. Elite Journal of Health Science, 2024; 2(2): 16-29
35. Obeagu EI, Amaeze AA, Ogbu ISI, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science, 2024; 2(2): 33-46
36. Obeagu EI, Obeagu, GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review, 2024; 2(1): 1-16
37. Kibaru EG, Nduati R, Wamalwa D, Kariuki N. Impact of highly active antiretroviral therapy on hematological indices among HIV-1 infected children at Kenyatta National Hospital-Kenya: retrospective study. AIDS research and therapy. 2015; 12:1-8.
38. Enawgaw B, Alem M, Addis Z, Melku M. Determination of hematological and immunological parameters among HIV positive patients taking highly active antiretroviral treatment and treatment naïve in the antiretroviral therapy clinic of Gondar University Hospital, Gondar, Northwest Ethiopia: a comparative cross-sectional study. BMC hematology. 2014; 14:1-7.
39. Gudina A, Wordofa M, Urgessa F. Immuno-hematological parameters among adult HIV patients before and after initiation of Dolutegravir based antiretroviral therapy, Addis Ababa, Ethiopia. Plos one. 2024; 19(10):e0310239.
40. Geletaw T, Tadesse MZ, Demisse AG. Hematologic abnormalities and associated factors among HIV infected children pre-and post-antiretroviral treatment, North West Ethiopia. Journal of blood medicine. 2017:99-105.
41. Jegede FE, Oyeyi TI, Abdulrahman SA, Mbah HA, Badru T, Agbakwuru C, Adedokun O. Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria. PLoS One. 2017; 12(3):e0174233.

42. Obeagu EI, Obeagu GU. ART and Platelet Dynamics: Assessing Implications for HIV Patient Care. Elite Journal of Haematology. 2024; 2(4):68-85.
43. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science. 2024;2(2):5-15.
44. Ciccacci F, Lucaroni F, Latagliata R, Morciano L, Mondlane E, Balama M, Tembo D, Gondwe J, Orlando S, Palombi L, Marazzi MC. Hematologic alterations and early mortality in a cohort of HIV positive African patients. PLoS One. 2020; 15(11):e0242068.
45. Ashenafi G, Tibebu M, Tilahun D, Tsegaye A. Immunohematological Outcome Among Adult HIV Patients Taking Highly Active Antiretroviral Therapy for at Least Six Months in Yabelo Hospital, Borana, Ethiopia. Journal of Blood Medicine. 2023:543-554.
46. Obeagu EI, Goryacheva OG. The Role of Inflammation in HIV and Sickle Cell Disease Co-Morbidity. Lifeline HIV, 2025; 3(1): 1-12
47. Obeagu EI, Goryacheva OG. Oxidative Stress in HIV and Sickle Cell Disease: A Double Burden. Lifeline HIV, 2025; 3(1): 13-24
48. Obeagu EI, Goryacheva OG. HIV and Sickle Cell Disease: A Focus on Liver Dysfunction. Lifeline HIV, 2025; 3(1): 25-40